risk upgrad equal-weight
transit new tam-driven valuat risk
long-term success dna-bas diagnost biopharma
invest space lower see path
sale rais pt rate equal-weight
sequenc grow support key govern agenc health insur
consum domin provid technolog sequenc dna
stand benefit seri market develop polici chang
emerg last year success dna-driven drug
administr immunotherapi cover david rising fda
support dna-bas companion cancer diagnost medicar expand
reimburs test cancer rare childhood diseas appear
tip point diagnost dna applic global pharma
govern fund dna analysi stronger growth outlook evidenc
recent nih eu commit growth research spend
consum interest dna-deriv applic inflect evidenc
growth consum test order last year grow global
research fund on-going mix shift toward genom research
new tam/valu framework appropri emb long-term
opportun consid share ytd rel tool
prior underweight thesi clearli flaw prior thesi overestim
impact new product novaseq util legaci instal base
underappreci stronger academic/pharma fund fail valu critic
new market take fresh look opportun clear
broaden support sequenc applic across faster-grow exist
market emerg market de-risk long-term outlook support
tam-driven approach valuat leverag longer term model
seri key market segment detail estim ilmn revenu
growth next year compar prior
year estim revenu respect
valuat impli price-to-earnings multipl ep compar
prior impli target ep current multipl consensu
ep pt rais also incorpor increas ep estim
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
market segment consid key assumpt model
approach assum sequenc ramp applic categori exhibit
pt broken clinic analysi baselin dna understand
diseas risk appropri drug prescript screening/monitor cancer
pathogen detect combin worth research genet
variant discoveri popul scale sequenc studi prove util worth
uptak matur categori continu steadi pace assum
new opportun penetr rate consist prior diagnost
screen predic also assum price per unit data continu
declin consist histor trend
exhibit clinic make major long-term tam-bas
revenu see long-term path
revenu end market mn
risk keep us bullish view valuat
histor multipl histor preced exhibit
suggest growth slow third year product cycl
would case launch novaseq timelin
market develop requir broader reimburs chang
challeng assess competit diagnostic/tool player
market prefer growth versu valu key consider ms equiti
strategist mike wilson note juli shift toward valu stock may
emerg risk higher multipl growth stock growth vs valu appear
jul shift could pressur growth stock coverag
present better opportun entri
model valuat chang summari rais revenu est
ep exhibit revenu est ep
vs consensu exhibit new price target base
tam-bas dcf use base wacc discount rate well
termin growth rate impli new ep
rais near year averag ntm multipl
current ntm consensu ep est mse
prior price target base yield premium
median tool comp impli ep
fundament intact valuat demand
fundament intact valuat demand
bull case ep
bull case ep
cancer prenat becom standard care next
month market penetr follow adopt curv like new drug
new diagnost test regulatori approv guidelin inclus drive
clinician adopt new approach cancer prenat care guidelin
revis support cancer prenat test uptak
reimburs clinic applic improv test standard
guidelin revis support medicar code refin research
market growth improv success penetr smaller lab
base case ep
base case ep
novaseq launch support near-term double-digit top-line growth
consum slow inflect oncolog remain event
uptak clinic applic remain concentr academ
commun hospit refin eas use new
softwar sampl prepar system on-going regulatori approv
guidelin inclus anticip emerg year research
market growth remain solid competit emerg longer term certain
bear case ep
bear case ep
growth slow ahead broader clinic adopt placement novaseq
slower expect demand prove limit outsid
major genom center uptak clinic applic remain
concentr academ commun center
refin eas use new softwar sampl prepar system
on-going reimburs clinic applic remain limit
privat pay group despit progress medicar code rate research
market turn flat govern budget pressur interest competit
platform grow threaten domin space
domin player next-
gener sequenc
expect broader applic
diagnost aid cancer prenat
applic longer term expect
traction measur ahead updat
clinic guidelin widespread
reimburs emerg
market like remain subdu due
physician group support clinic
guidelin evolut broader adopt
clinic set look public
expert consortia clinic trial
fda insur support includ
regulatori approv standard test
posit reimburs polici
expand interest research tailor
innov sampl prepar
softwar support adopt user
smaller clinic hospit
meaning competit emerg
medium term
clinic trial readout
support broader human sequenc
limit diagnost oncolog
increas trend sourc sequenc
lab limit instrument demand
risk achiev price
clinic trial ahead timelin
updat clinic guidelin support
demonstr lower expect valu
broad use oncolog applic
slowdown research channel
longer term opportun undeni view introduc report
new model ilmn sequenc system opportun combin seri
revenu forecast genomics/dna sequenc sub-market analysi reflect
forecast sequenc uptak substitut exist technolog select
exist market government/academ research pharma/biotech
genealogy/ancestri test today enabl new market develop
emerg clinic applic summar forecast provid
detail subsequ section report tam-bas revenu model drive
simplifi dcf drive valuat assum revenu convert
cash sale equal weight averag comp target categori
across tool diagnost lab peer leverag wacc base
busi discount rate wellness/asymptomat screen assum
exhibit end market revenu shift toward clinic
revenu end market mn
consid sourc fund model look growth term
penetr vs sourc fund top-down view across academ pharma/biotech
appli market take unit-driven bottom-up view consum genom
test clinic genom test growth base past technolog s-curv uptak
end market analysi suggest largest pool fund pursu
potenti dtc health/wel govern health-rel
exhibit howev see applicability/penetr consum
spend rel low particularli perceiv util clinic sequenc
grow time ultim see key end market long-term
growth subsum consum applic degre see sequenc reach
penetration/shar in-vitro diagnost ivd manufactur market
larg driven hospit spend exhibit also continu gain
share academic/govern pharma/biotech fund research shift
sequencing-bas analys though conserv see penetr
pool fund
exhibit end market fund categori target
penetr end market fund
asymptomat disease/risk screen largest potenti opportun
also uncertain outlin primari sub-market clinic genom
market see compet pre-nat test carrier screen nipt
new born screen tumor profil wellness/asymptomat screen healthi
microbiology/infecti diseas test clinic tam model assum
reach clinic revenu driven
genom screen healthi patient modern healthcar system major
diseas includ cancer part routin annual physic
exhibit see clinic market import wellness/asympomat
screen potenti largest opportun also uncertain
near-term risk revolv around novaseq replac cycl sustain revenu
growth key driver valuat investor percept asset
larg degre histor driven new instrument
products/replac cycl one notabl near-term risk likelihood revenu
slow comp get tougher near-term like cannib
legaci system novaseq grow evid faster legaci
instrument decommiss custom begin swap experi
effici novaseq quarter thesi broken past product cycl
suggest overal growth tend deceler quarter new
high-throughput instrument launch align exhibit though
new underli growth driver util kick cycl
off-set includ greater tmb/io tumor profil fmi medicar coverag
initi surg consum interest ancestri dtc test ramp population-
scale sequenc project countries/govern entiti grow uptak liquid
biopsi clinic
exhibit sequenc revenu typic fall back-half second year post-new
instrument launch period enter novaseq
quarter
model valuat chang summari transit new application-driven
valuat model rais revenu estim driven
grow novaseq pullthrough clinic custom tumor profil liquid
biopsi higher servic revenu pharma dtc custom ep goe
higher driven revenu chang see chang exhibit
revenu estim ep estim vs
consensu see new driver make estim de-risk exhibit view new
ep guidanc still conserv consid recent gross margin trend oper
expens disciplin continu tax beat see consensu similarli conserv
near-term use new long-term tam-bas model direct inform
estim though note directli link model fail consid
near-term dynam instrument replac cycl instead focus long-term
driver underli util
risk upsid downsid notabl upsid risk popseq/larg scale
china precis medicin initi ramp faster vs manag expect
limit impact near-term liquid biopsi enter widespread clinic use key
downsid risk relat primarili faster decommiss legaci instrument due
novaseq lower associ consum revenu stream
exhibit chang forecast
rev
rev
rev
rev
rev
rev
much end market worth pt broken
clinic analysi baselin dna understand risk diseas appropri
drug prescript screen cancer cancer monitor pathogen detect
combin worth research genet variant discoveri popul
scale sequenc studi prove util patient subset worth
 exhibit assum uptak matur categori
continu steadi pace assum new opportun penetr rate
consist prior diagnost screen predic also assum price per
unit data continu declin consist histor trend
exhibit clinic make major tam-bas dcf price particularli
due signific well screen opportun
valuat highli depend clinic particularli path well screen
view clinic import market sustain growth make
half pt well screen far import
compon consid higher degre uncertainti around
wellness/asymptomat screen market appli higher discount rate
stream cash flow dcf rest tam discount
calcul wacc even elev discount rate well screen make
valu dcf
leverag longer term model seri key market segment
estim ilmn revenu growth next year compar
prior year estim revenu
respect new price target base tam-bas dcf use
wacc non-wel screen cash flow discount rate well
screen cash flow termin growth rate impli new ep
year averag ntm multipl current ntm multipl
prior price target base yield
premium median tool comp impli ep
clinic oncolog market enter mainstream
precis medicin becom increasingli viabl last year clinician
consensu held ultim dna analysi would critic cancer treatment
cancer manifest malign dna mutat last year
array marker valid enabl treatment signific subset
patient key uptak sequenc cancer treatment howev part
tie recent polici decis last month fda approv assay
fmi address key barrier use
reimburs sequenc cancer treatment regulatori approv
time medicare/medicaid introduc relat reimburs polici
favor fda approv test also offer pathway use non approv
test valid relev agenc reimburs polici
treat late stage cancer case unlock key segment market present
investor valid potenti greater progress time fda
expert/aacr dilig takeaway importantli fda also approv
assay use complex genom signatur tumor molecular burden
tmb help diagnos patient appropri immunotherapi
other move jointli confirm regulatori support open door
broader guidelin support sequenc cancer treatment wrap fda
approv shape landscap
tumor profil rx selection/monitor via genom grow market global
spend oncolog drug per year rel area
pharmacotherapi cancer drug less like effect given patient
latest cancer therapi cost per month surgic treatment
cost per patient creat power incent invest better
diagnost assess prognosi given cancer patient benefit
given therapi current standard care tumor assess via
patholog offer data cancer physic attribut stage grade marker
progress truli reliabl assess prognosi appropri path
therapi precis cost-effect approach administ drug patient
like benefit therapi assess via companion
diagnost analyz patient tumor dna retrospect review suggest
administr drug companion diagnost guidanc take respons rate
cancer
asymptomat screen potenti largest market also uncertain
outlin primari sub-market clinic genom market see
tumor profil wellness/asymptomat screen healthi patient cancer
microbiology/infecti diseas test clinic tam model assum
reach clinic revenu driven genom
screen healthi patient modern healthcar system major diseas
cancer part routin annual physic market potenti even larger
consid screen test becom standard care mammogram breast
cancer screen women colonoscopi colon cancer screen done
us popul accord jama said also uncertain
market outlin consid larg exist today form
envis though liquid biopsi test approach commerci
could take form result high degre uncertainti around
wellness/asymptomat screen market appli higher discount rate
stream cash flow dcf rest tam discount
calcul wacc
exhibit see clinic market import wellness/asympomat
screen potenti largest opportun also uncertain
expect consum clinic demand driver intersect time elast curv
clinic genom test clearli still evolv consumer/pati educ
import recent survey genomeweb person medicin coalit
suggest us popul would will pay least
pocket whole genom sequenc test though would will pay
anyth clinic util studi produc payor coverag clinic
test ramp like widespread adopt test
exhibit survey suggest us popul would will pay least
pocket whole genom sequenc test though would will pay anyth
popul will pay pocket whole-genom
will
will
pay
genomeweb person medicin coalit survey adult repres us popul morgan stanley research
will
pay
will
pay
will
pay
will
pay
will
pay
exhibit liquid biopsi could supplier instruments/reag current price address popul exclud
much larger asymptomat screen opportun
market encompass western europ canada china australia korea japan
outlin pharma demand back broader biopharma space larg
grow sourc spend drug develop one increasingli focus
dna marker tool identifi right patient therapi clearest
cancer trend like becom broader marker rang neurolog
cardiovascular diseas emerg coverag note progress alreadi
made see genesight deploy genom test aid clinician
prescrib drug depress anxieti success valid broader
biopharma complex trend toward fda approv dna-target therapi
success rate dna-mark driven patient recruit effort import
use technolog drug discoveri valid process
exhibit current drug develop market spend in-
hous pharma expect genom compani go
pre-clin develop discoveri bucket spend near-
exhibit pre-clin develop discoveri spend
grow compound-annual-growth-rate
recoveri begun pharma fund growth acceler evid year
come function better end-us demand see stabil small molecul
gener disrupt post wave competit driven fda approv
prior pharma headwind drug pricing/tax reform polici uncertainti sever
fail clinic trial fulli lap least near-term see drug
price polici expert time dilig find greater accept
biomarker-depend drug develop pathway see dilig inher
tools-intens particularli wake mrk/keytruda cover david
rising approv molecular indic includ tmb msi-high
insur commun increasingli value-sensit pricing/ti drug spend
think tool insul drug price polici headwind emerg
lower price could also lead pharma compani util biomark increas
trial effici success posit tool
fund continu acceler support ventur capit invest
biotechnolog hit record-high pwc estim vc
spend biotech us compar total spend global
forecast ms-cover compani pharma/biotech morgan stanley
estim compani cash off-shore repatri
associ tax reform could drive increas spend addit
 a/strateg activ note biotech vc invest support growth early-
stage player develop orphan drug expens compound
exhibit vc invest continu acceler
exhibit orphan design indic surg
orphan indic design orphan drug
orphan idic approv drug
iqvia institut april morgan stanley research
biomark power evolut patient drug develop rapid rise
applic biomark increas develop confid success drug
develop effort histor analysi drug trial suggest phase clinic
trial includ use biomark like succeed survey
work suggest biomark increasingli part drug develop program
increas use biomark oncolog immuno-oncolog
therapi use biomark also translat drug develop effort
approv stream predict biomark use new activ
substanc launch see trend evid drug approv
process chang way drive greater predict drug develop
sustain chang outlook pharma channel
exhibit cdx shown promis drive efficaci drug
exhibit survey respond indic increas use
biomark oncolog drug
averag rate increas use biomark drug
olsen dana jorgensen jan trost companion diagnost target cancer drug clinic
regulatori aspect frontier oncolog morgan stanley research
alphawis morgan stanley research
iqvia im cover ricki goldwass forecast us/glob spend medicin
grow compound-annual-growth-rate global net spend medicin
expect reacceler growth growth suggest
direct market improv despit forecast bit less robust prior
report growth driven biolog sale expect grow faster
convent drug
exhibit im forecast global net spend medicin see compound-annual-growth-rate
total global spend medicin bn
iqvia institut march morgan stanley research
content expans via deregul led acceler growth
number new develop help drive acceler dtc
test growth growth new user accord data
assum asp test kit subscript associ promot
holiday season impli dtc test market cross revenu
threshold primari supplier mani dtc lab also saw
strong growth space estim revenu dtc end market
doubl total revenu driver behind
acceler market growth includ expans content beyond genealog
includ health-risk relat applic launch helix enabl
accommod fda regulatori regim advertis growth
exhibit estim consum genom histor volum
sampl genotyp sequenc date
stage life-cycl consum genom see genealog servic larg
recreat good fungibl consum entertain media go
pre-exist bucket spend would provid larg market theoret target
high-incom adult consum interest genet long-term bottom-up
approach look path subscriber/instal base growth consum
genom vs preced consum discretionari technolog includ fit
wearabl amazon prime xbox live digit music stream suggest
consum remain earli inning adopt vs preced assum
target popul consum genom on-line popul given
similar minimum requir term wealth market access penetr
near past adopt curv suggest penetr
inflect typic occur mindshar reach critic mass
ultim dtc trailblaz clinic genom long-term see dtc
test mean drive broader awar genom precis medicin
ultim subsum clinically-integr approach similar pursu
color genom fact consum pay
pocket famili histori genotyp tell us would self-pay market
broader clinic sequenc right price point though like yet
cost patient continu come continu bend cost
curv toward genom next year payor polici emerg one
area dtc hold advantag clinic player amass larg
consumer/pati databas use biopharma compani drive pre-
clinic discoveri biomark smart match patient clinic trial
acceler trial timelin save cost
exhibit penetr consum genom on-line popul
suggest earli inning growth inflect frequent occur penetr
notebook penetr pc
digit penetr music sale
xbox live penetr video game consol
smartphon penetr handset
wearabl penetr smartphon
netflix penetr broadband household
exhibit preced technolog uptak curv could suggest consum genom remain
earli phase growth suggest may wide sought consum
consum technolog uptak curv mn user
exhibit benchmark potenti consum spend genom vs wearabl exist bucket digit spend suggest consum
genom market growth expect overli demand
genom consum well spend
wearabl consum well spend
long-term academic/govern fund environ look healthi last
year consist commit near- long-term growth academ
research emerg across key market us europ china bipartisan
support us congress research fund becam evid white
hous challeng nih fund ad level comfort commit
nih broader cancer research fund even prior action centuri
cure act author fund cancer moonshot
europ commit horizon horizon europ give us
msd fund disburs visibl horizon europ show
invest five-year area biolog cell therapi well
announc commit precis medicin program next
exhibit larger scale gwa studi grow late total gwa studi pass
sampl
exhibit fund disburs us treasuri nih
robust vs still strong overal
exhibit us/eu domin term health spend though
china increasingli part mix
gross domest expenditur health bn
valuat methodolog risk
exhibit valuat rel expect forward ebitda
exhibit valuat rel expect forward growth
thomson reuter morgan stanley research
thomson reuter morgan stanley research
look expens near-term estim expect upward revis
consensu expect investor remain long-term focus expect
growth consensu faster rel coverag multipl
stock yield suggest stock less attract other
coverag near/medium-term metric view support call near-
term downsid stock consid expect on-going upward revis
consensu see exhibit ep estim consensu
dialogu investor suggest broad appreci longer term
potenti critic near term trend
thomson reuter morgan stanley research
thomson reuter morgan stanley research
tactic context stock suggest near term upsid like mute rel tool
peer current ntm price-to-earnings multipl histor premium
histor premium rel trade
histor premium histor premium see
ep grow next year roughli in-lin trail
ev/ebitda current trade consensu ebitda vs
tools/diagnost comp trade mostli appear justifi given expect
grow ebitda next year higher
peer also trade yield compar median
yield tools/dx comp reflect appreci growth vs
walk price target view rel long-term
model pt impli trade ep current ntm
price-to-earnings multipl trail averag multipl expect multipl
remain somewhat lower rel histori forecast call somewhat
modest growth top line histori
deriv price target leverag longer term model seri key
market segment estim ilmn revenu growth next
year compar prior year estim revenu
respect new price target base
tam-bas dcf use wacc non-wel screen cash flow
discount rate well screen cash flow termin growth rate
thomson reuter morgan stanley research
price target base tam-bas dcf model use termin
growth rate wacc base busi wacc well
screen model assum revenu convert cash sale equal
weight averag comp target categori across tool diagnost lab
peer view base uptak clinic applic remain
concentr academ commun hospit refin
eas use new softwar sampl prepar system on-going
regulatori approv guidelin inclus anticip emerg
research market growth remain limit competit emerg medium
valu driver includ physician group support clinic guidelin evolut
broader adopt system includ public expert consortia
clinic trial group fda insur support includ regulatori approv
standard test posit reimburs polici expand interest research
support tailor genom guid therapi innov sampl
prepar softwar support adopt user smaller clinic hospit
risk price target includ clinic trial guidelin timelin hospit
govern budget constraint new competit
assum revenu academic/govern custom convert
ratio similar histor averag given histor depend market
assum pharma/biotech appli revenu convert convert
ratio similar tool peer revenu market assum consum
revenu convert ratio similar lab given larg servic compon
embed market assum clinic revenu convert
ratio similar establish ivd manufactur
termin growth rate
equiti
after-tax cost debt
well discount valu total
base discount valu total
less debt minor interest
add invest
exhibit convers sale tool dx lab peer rang
averag
thomson reuter research estim
act financi advisor bristol myer squibb compani bristol
myer connect transfer billion pension oblig
prudenti insur compani america compani
announc septemb transact subject customari close condit
bristol myer agre pay fee financi servic pleas
refer note end report
number million except per share number unless otherwis indic
penetr academ fund
penetr pharma fund
penetr appli fund
penetr dtc well spend
penetr clinical/ivd
cycl sp flowcel
mvp enrol particip
sequenc
genom mark feb
acceler exom end instead
enrolle date
sequenc
expect complet
extend ra panel vectibix
phase analysi servic whole-genom
compani data morgan stanley research
genom
dna sampl collect genom plan
strive trial women
philip data health system
us gr launch gr row
sampl year genom total
genom per year pilot project commenc pilot project
three year
sequenc look
complet expect june target
buy edico genom
ccga expand patient
bgi buy pacbio sequel system long read
launch genestudio sequenc new assay
